戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 t rapidly initiate inflammation and vascular fluid loss.
2 al increase in protein concentrations due to fluid loss.
3 siological parameters can be used to predict fluid loss.
4 icate the intestinal lumen while restricting fluid loss.
5 his is a novel mechanism to limit intestinal fluid loss.
6 ime it is in place, decreasing cerebrospinal fluid loss.
7 ers at 24 h, despite greater weight loss and fluid loss.
8 layer, the osmotic pressure of which opposes fluid loss.
9 e used in the assessment of response to body fluid loss.
10 n epidermal barrier function to prevent body fluid loss.
11 ortant to ensure compensation for extrarenal fluid losses.
12 d is distinct from hypovolemia due to excess fluid losses.
13 tate rehydration efforts by limiting further fluid losses.
14  min, at a rate that replaced a third of the fluid losses.
15 .1 kg vs. 3.1 +/- 3.5 kg; p = 0.001) and net fluid loss (4.6 vs. 3.3 l; p = 0.001) were greater in th
16 protein (1.5 vs. 0.5 g/dL at day 3), and net fluid loss (-5480 vs. -1490 mL at day 3) throughout the
17 r properties and can result in intravascular fluid loss and edema.
18 al and viral diseases consists of correcting fluid loss and electrolyte imbalance by oral or parenter
19 mic disease scores that correlated with tear fluid loss and eyelid edema.
20 T-L4-deficient newborn mice had greater body fluid loss and higher mortality in a trans-epidermal bod
21  a physiological role for NDR1 in preventing fluid loss and maintaining cell integrity through plasma
22 osemide with placebo for 72 hrs, titrated to fluid loss and normalization of serum total protein conc
23 ture, high-pressure (HTHP) conditions due to fluid loss and property degradation.
24 Upon cooling, the pores contract to restrict fluid loss and restore operation.
25              In humans, drinking replenishes fluid loss and satiates the sensation of thirst that acc
26 orrelation between either weight loss or net fluid loss and symptom relief, (r=0.04; P=0.54 and r=0.0
27                                 Weight loss, fluid loss, and NT-proBNP reduction at 72 hours are poor
28 of decongestion at 72 hours-weight loss, net fluid loss, and percent reduction in serum N terminal B-
29            Secondary end points included net fluid loss at 48 h, functional capacity, HF rehospitaliz
30 improved PV by 27.84%, YP by 43.16%, reduced fluid loss by 54.16%, and mud cake thickness by 25%.
31 nt along the Nobeoka Thrust after this small fluid-loss by the extensional crack formation does not e
32 ptan resulted in greater weight loss and net fluid loss compared with placebo, but tolvaptan-treated
33 those containing a liquid dispersant, liquid fluid loss controller, liquid anti-gas migration, and li
34 ea of carotid and femoral arteries caused by fluid loss during haemodialysis (HD) and to determine th
35 nown regarding innate mechanisms that dampen fluid loss during PMN-endothelial interactions.
36   Excessive activation results in intestinal fluid loss during secretory diarrheas, whereas CFTR muta
37       We were able to measure changes due to fluid loss during the HD session.
38 from serial measurements are consistent with fluid loss for both ED and ID conditions.
39 he drug concentration dilution caused by the fluid loss from blood stream in the tumour region around
40 polysaccharide of synovial fluid, attenuates fluid loss from joints as joint pressure is raised ('out
41 (HA), a component of synovial fluid, buffers fluid loss from joints.
42 ease at early times after CA-4-P, suggesting fluid loss from the blood.
43 s the toxin responsible for inducing massive fluid loss from the human host.
44 n NHE3-dependent manner and restored the net fluid loss in a mouse model of acute diarrhea.
45 f cystic fibrosis and in reducing intestinal fluid loss in cholera and other secretory diarrheas.
46 Ou and FVB/N was associated with significant fluid loss in feces, a remarkable downregulation of Slc2
47 toxins may cause life-threatening diarrhoeal fluid loss in part because they stimulate enterocytes to
48 ycystic kidney disease and reduce intestinal fluid loss in secretory diarrheas.
49 of CaCC functions and in reducing intestinal fluid losses in CaCC-mediated secretory diarrheas.
50 CFTR inhibition might also reduce intestinal fluid losses in cholera and possibly in other infectious
51 ntoxic CFTR inhibitors may reduce intestinal fluid losses in cholera.
52 ctrolyte supplement attenuated extracellular fluid losses, increased exercise duration and increased
53 retion accounted for less than 30% of plasma fluid loss indicating that reduced albumin permeability
54 cluding depressing stroke volume, increasing fluid loss into the intestine, and increasing inflammato
55 inking water in response to thirst following fluid loss is a pleasant experience.
56 ough the assessment of daily weights and net fluid loss is the current standard of care, yet the rela
57 % confidence interval, 0.90-0.99 per 1000 mL fluid loss; NT-proBNP hazard ratio, 0.95; 95% confidence
58 free balanced crystalloid for replacement of fluid losses on the day of major surgery was associated
59 uantitative projections of fluid therapy and fluid losses on the patient's serum sodium, balances pot
60 cation and greatly attenuates trans-synovial fluid loss (outflow buffering).
61 se, and outperformed clinically obtained net fluid loss (p < 0.05 for all cutpoints).
62  the first 72 to 96 hours, there was greater fluid loss (P=0.001), decrease in NT-proBNP (N-terminal
63 ssically attributed to an increased diuretic fluid loss, recent studies support fluid redistribution,
64 A transition are not associated with massive fluid loss, suggesting the existence of a mechanism that
65 d higher mortality in a trans-epidermal body fluid loss test.
66 iltration safely produces greater weight and fluid loss than intravenous diuretics, reduces 90-day re
67 rmeability, enhancing the ability to control fluid loss under simulated drilling conditions.
68 an tubule secretion and restricts organismal fluid loss, whereas injection of DH37 or DH47 reverses t
69 acellular fluid volumes, and attenuated body fluid losses while maintaining sweating rates.